NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited Consolidated Condensed)
(in thousands, except share and per share
data or as otherwise noted herein)
(1) Basis of Presentation
The accompanying unaudited
consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”,
“we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments)
which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the
interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence,
LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the three months
ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.
These financial statements
should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2022, included
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange
Commission.
(2) Description of Business
Nanophase Technologies
Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven
company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”),
is focused in various beauty- and life-science markets. Using consumer health as our end-goal and science and innovation
to guide the path, skin health and medical diagnostics combined currently make up the majority of our business and drive our forward
growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated
family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and
“non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients
and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science
subsidiary. In terms of our life sciences focus, we have seen demand decrease for our medical diagnostics ingredients. Additionally,
we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant
additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics,
fall into the advanced materials product category.
We target markets, primarily
related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we
believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with
current customers in these target markets to identify their material and performance requirements. We market our materials to various
end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.
Recently developed
technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on
a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became
the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™
now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™
— all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of
our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts
include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies
Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell
fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets,
in addition to the ingredients we have traditionally sold in the personal care area.
Although our primary
strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to
expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.
While product sales
comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not
expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue”
in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products.
(3) Revenues
Revenues are recognized
when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive
in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping
point almost universally, is the point in time at which we recognize the related revenue.
We generally expense
sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within
selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized
when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of
operations.
Contract balances at March 31, 2023, December 31, 2022, and
December 31, 2021 are as follows:
| |
Accounts Receivable, net
of Unbilled | | |
Contract
Assets | | |
Contract
Liabilities | |
Balance, December 31, 2021 | |
$ | 3,937 | | |
$ | 179 | | |
$ | 1,444 | |
Balance, December 31, 2022 | |
| 4,734 | | |
| — | | |
| 2,188 | |
Balance, March 31, 2023 | |
| 4,380 | | |
| — | | |
| 1,842 | |
Revenue recognized
in the reporting period that was included in the contract liability balance at the beginning of the period was $1,297 and $123
for the three months ended March 31, 2023 and 2022, respectively.
Other revenue may include
revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized
over time when the obligations under the agreed upon contractual arrangements are performed on our part. Other revenue recognized
over time was $121 and $110 for the three months ended March 31, 2023 and 2022, respectively.
(4) Earnings Per Share
Options to purchase
approximately 1,164,000 shares of common stock that were outstanding as of March 31, 2023 were not included in the computation
of earnings per share for the three months ended March 31, 2023, as inclusion of these shares would have resulted in an anti-dilutive
effect and were thus omitted from disclosure. Options to purchase approximately 2,080,000 shares of common stock that were
outstanding as of March 31, 2022 were included in the computation of earnings per share for the three months ended March 31, 2022.
Earnings applicable to common stock and common stock shares
used in the calculation of basic and diluted earnings per share are as follows:
| |
|
|
|
|
| |
| |
Three months ended
March 31, | |
| |
2023 | | |
2022 | |
Numerator: (in Thousands) | |
| | |
| |
Net (loss) income | |
$ | (1,159 | ) | |
$ | 62 | |
| |
| | | |
| | |
Denominator: | |
| | | |
| | |
Weighted average number of basic common shares outstanding | |
| 49,429,407 | | |
| 48,984,312 | |
Weighted average additional shares assuming conversion of in-the-money stock options to common shares | |
| — | | |
| 2,080,000 | |
Weighted average number of diluted common shares outstanding | |
| 49,429,407 | | |
| 51,064,312 | |
| |
| | | |
| | |
Basic earnings per common share: | |
| | | |
| | |
Net (loss) income per share – basic | |
$ | (0.02 | ) | |
$ | 0.00 | |
Diluted earnings per common share: | |
| | | |
| | |
Net (loss) income per share – diluted | |
$ | (0.02 | ) | |
$ | 0.00 | |
(5) Financial Instruments
We
follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for
measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization
of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level
1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.
Our
financial instruments include cash, cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any
short-term and long-term borrowings as described in Note 6. The carrying values of cash and cash equivalents, accounts receivable,
and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value
of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.
There
were no financial instruments adjusted to fair value on March 31, 2023, or December 31, 2022.
(6) Notes and Lines of Credit
Notes and lines of credit consist of the following:
| |
| | |
As of March 31, 2023 | | |
As of December 31, 2022 | |
| |
Rate | | |
Available | | |
Outstanding Balance | | |
Available | | |
Outstanding Balance | |
Libertyville Bank & Trust (1) | |
| 9.00 | % | |
| 30 | | |
| — | | |
| — | | |
| — | |
Libertyville Bank & Trust (2) | |
| 9.00 | % | |
| 500 | | |
| — | | |
| — | | |
| — | |
Strandler, LLC (3)(4) | |
| 8.75 | % | |
| 1,000 | | |
| 1,000 | | |
| 1,000 | | |
| 1,000 | |
Beachcorp, LLC (3)(5) | |
| 8.75 | % | |
| 4,614 | | |
| 2,893 | | |
| 4,392 | | |
| 4,282 | |
Beachcorp, LLC (3)(6) | |
| 8.75 | % | |
| 4,000 | | |
| 4,000 | | |
| 4,000 | | |
| 3,000 | |
| 1) | Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime
rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have
been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding
on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet. |
| 2) | The Company maintains a credit agreement with Libertyville which most recently served the primary purpose of insuring that
it met its cash balance requirements at quarter end relating to a contract with the Company’s largest customer. Interest
on drawn balances was at the prime rate plus 1%. On December 21, 2021, the existing credit agreement with Libertyville
was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois.
Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2023. We expect
to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the
Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC. |
| 3) | On November 16, 2018, we entered into a Business Loan Agreement
(the “Master Agreement”) with Beachcorp, LLC. The Master Agreement relates to two loan facilities, each evidenced by a
separate promissory note dated as of November 16, 2018: a term loan to the Company of up to $500 to
be disbursed in a single advance (the “Term Loan”) with a fixed annual interest rate of 8.25%,
payable quarterly, and with principal due on December
31, 2020; and an asset-based revolving loan facility for the Company of up to $2,000 (the
“A/R Revolver Facility”), with floating interest accruing at the prime
rate plus 3%
(8.25%
minimum) per year, with a borrowing base consisting of qualified accounts receivable of the Company, and a maturity of March 31, 2020, as amended. On March 23, 2020, the Company and Beachcorp, LLC executed the First Amendment to our Master
Agreement that extended the maturities of both the Term Loan and the A/R Revolver Facility to March 31, 2021. Effective
September 8, 2020, the Company and Beachcorp, LLC executed the Second Amendment to our Master Agreement that expanded the limit on
the A/R Revolver Facility from $2,000 to
$2,750. On December 23, 2020, the Company and Beachcorp, LLC executed the Third Amendment to our Master Agreement that
expanded the limit on the A/R Revolver Facility from $2,750 to $4,000 and extended the maturities of both the Term Loan
and the A/R Revolver Facility to March 31, 2022. Effective April 21, 2021 the Company and Beachcorp, LLC executed the Fourth
Amendment to our Master Agreement that expanded the limit on the A/R Revolver Facility from $4,000 to $6,000, changed the
interest rate to fully floating and reduced the rate to the prime rate plus 2%, also extending the maturity of the
A/R Revolver Facility to March 31, 2023. This amendment also increased the amount of the Term Loan from $500 to $1,000,
changed the interest rate to fully floating and reduced the rate to the prime rate plus 2%. The maturity of the Term
Loan remained March 31, 2022. The Term Loan and A/R Revolver Facility are secured by all the unencumbered assets of the Company
and subordinated to Libertyville’s secured interest under the New Business Loan Credit Agreement. The Master Agreement
substantially restricts the Company’s ability to incur additional indebtedness during the terms of both the Term Loan and the
A/R Revolver Facility. |
| 4) | On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”)
with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp,
LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an
affiliate of Bradford T. Whitmore. |
| 5) | On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”),
which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence
the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000,
reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March
31, 2024. |
| 6) | On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory
Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing
amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory
of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. |
Beachcorp, LLC and Strandler, LLC are affiliates
of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R.
Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the
Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the
Company’s credit facility with Libertyville Bank & Trust.
On May 1, 2023 the
Company entered into another promissory note (the “Non-Revolving Note - TI Agreement”) with Beachcorp, LLC in the amount
of $1,750,000 with an interest rate of the prime rate plus 0.75%. The note matures on September 30, 2023. This loan is for work
being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement.
Related party interest summary:
| |
|
|
|
|
| |
| |
Three Months Ended March 31, | |
| |
2023 | | |
2022 | |
Interest expense, related parties | |
$ | 150 | | |
$ | 39 | |
Accrued interest expense, related parties | |
| 59 | | |
$ | 16 | |
(7) Inventories
Inventories consist
of the following:
| |
March 31, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Raw materials | |
$ | 5,637 | | |
$ | 6,797 | |
Finished goods | |
| 2,481 | | |
| 2,041 | |
Total Inventories, net | |
| 8,118 | | |
| 8,839 | |
At March 31,
2023 and December 31, 2022, the Company applied a $500 reserve against reported inventory to account for excess and obsolete inventory.
(8) Lease Commitments
The Company’s
operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s
leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates
the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option
in our lease term. Since inception of our newest leased building, we have subleased a portion of the unused floorspace on a temporary
basis. This sublease may convert to a month-to-month lease upon expiration.
As of March 31, 2023,
the ROU asset had a balance of $8,714,
which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and
current and non-current lease liabilities related to the ROU asset of $0
and $9,751,
respectively. The $0
in current lease liability stems from expected payments from the lessor of the Bolingbrook facility reimbursing the Company for
tenant improvement allowances in the amount of $1,716
over the next twelve months. Because the expected cash payments over the next twelve months resulted in an amount exceeding a
current liability, the current operating lease liability line item on the balance sheet reported $0,
with the balance exceeding the current liability netted against the noncurrent portion for a total operating lease liability at
March 31, 2023 of $9,751.
As a result, the total lease liability was reduced by the expected payment, the net effect of reimbursements received, and cash paid
for leases over the next twelve months resulting in net lease payments of $347.
As of December 31, 2022, the ROU asset had a balance of $8,978
which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and
current and non-current lease liabilities related to the ROU asset of $0
and $9,823,
respectively. The $0
in current lease liability stems from expected payments from the lessor of the Bolingbrook facility reimbursing the Company for
tenant improvement allowances in the amount of $1,957
over the next twelve months. As a result, the total lease liability was reduced by the expected payment, the net effect of
reimbursements received, and cash paid for leases over the next twelve months, resulting in net lease payments of $97.
Discount rates used
for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s
portfolio.
The office leases contain
variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid
based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease
and non-lease components for building leases.
Quantitative information regarding the
Company’s leases is as follows:
| |
Three Months Ended March
31, 2023 | | |
Three Months Ended March 31, 2022 | |
Components of lease cost | |
| | | |
| | |
Finance lease cost components: | |
| | | |
| | |
Amortization of finance lease assets | |
$ | — | | |
$ | 11 | |
Interest on finance lease liabilities | |
| — | | |
| 2 | |
Total finance lease costs | |
| — | | |
| 13 | |
Operating lease cost components: | |
| | | |
| | |
Operating lease cost | |
| 469 | | |
| 363 | |
Variable lease cost | |
| 146 | | |
| 172 | |
Short-term lease cost | |
| 48 | | |
| 21 | |
Sublease income | |
| (196 | ) | |
| (183 | ) |
Total operating lease costs | |
| 467 | | |
| 373 | |
Total lease cost | |
$ | 467 | | |
$ | 386 | |
Supplemental cash flow information related
to leases is as follows for the three months ended March 31, 2023 and 2022:
| |
2023 | | |
2022 | |
Cash paid for amounts included in the measurement of lease liabilities: | |
| | | |
| | |
Operating cash outflow from operating leases | |
$ | 263 | | |
$ | 190 | |
| |
| | | |
| | |
Weighted-average remaining lease term-finance leases (in years) | |
| — | | |
| 0.6 | |
Weighted-average remaining lease term-operating leases (in years) | |
| 8.0 | | |
| 9.3 | |
Weighted-average discount rate-finance leases | |
| — | | |
| 7.6 | % |
Weighted-average discount rate-operating leases | |
| 7.05 | % | |
| 7.5 | % |
The future maturities of the Company’s
finance and operating leases as of March 31, 2023 are as follows:
| |
| |
2023 | |
$ | (172 | ) |
2024 | |
| 2,029 | |
2025 | |
| 1,473 | |
2026 | |
| 1,471 | |
2027 | |
| 1,510 | |
Thereafter | |
| 7,162 | |
Total payments | |
$ | 13,473 | |
Less amounts representing interest | |
| (3,722 | ) |
Total minimum payments required | |
$ | 9,751 | |
(9) Stock-Based Compensation
We follow ASC Topic 718, Stock-Based Payments,
in which compensation expense is recognized only for stock-based payments expected to vest.
| |
|
|
|
|
| |
| |
Three
months ended March
31, | |
| |
2023 | | |
2022 | |
Stock-based compensation expense | |
$ | 209 | | |
$ | 148 | |
Remaining unrecognized compensation expense | |
$ | 1,577 | | |
| | |
Remaining weighted average-period, expense recognition (years) | |
| 2.1 | | |
| | |
The following table summarizes the option activity
for our employees and directors during the three months ended March 31, 2023:
Schedule of option activity
| |
| | |
Weighted | |
| |
| | |
Average | |
| |
| | |
Exercise Price | |
Options | |
Shares | | |
per Share | |
Outstanding on January 1, 2023 | |
| 3,443,661 | | |
$ | 1.33 | |
| |
| | | |
| | |
Granted | |
| — | | |
$ | — | |
Exercised | |
| (199,891 | ) | |
| | |
Forfeited or expired | |
| (18,000 | ) | |
| | |
| |
| | | |
| | |
Outstanding on March 31, 2022 | |
| 3,225,770 | | |
$ | 1.37 | |
(10) Significant Customers and Contingencies
The portion
of total revenue from our significant customers are as follows for the periods ending March 31, 2023, and 2022:
| | |
| |
For the three months ended | |
| | |
| |
March 31, | |
Customer # | | |
Product Category | |
2023 | | |
2022 | |
1 | | |
Personal Care Ingredients | |
| 37 | % | |
| 29 | % |
2 | | |
Solésence® | |
| 11 | % | |
| 18 | % |
3 | | |
Solésence® | |
| 5 | % | |
| 13 | % |
4 | | |
Solésence® | |
| 9 | % | |
| 9 | % |
| | |
Total | |
| 62 | % | |
| 69 | % |
Accounts receivable balances for these four customers were approximately:
| | |
| |
For the three months ended
March 31, | |
Customer # | | |
Product Category | |
2023 | | |
2022 | |
1 | | |
Personal Care Ingredients | |
$ | 1,197 | | |
$ | 1,489 | |
2 | | |
Solésence® | |
| 548 | | |
| 880 | |
3 | | |
Solésence® | |
| 424 | | |
| 1,050 | |
4 | | |
Solésence® | |
| 485 | | |
| 371 | |
| | |
Total | |
$ | 2,654 | | |
$ | 3,790 | |
We
currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies
outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to
the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we
fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer
right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring
a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or
the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s
net book value, depending on the equipment and related products.
If
a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would
receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue
and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment
that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any
additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets
as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached
certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our
key staff and line employees due to economic realities. We believe that our employees are a critical component of our success,
and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain
skilled employees given the stigma relating to such an event and its impact on us.
(11) Business Segmentation
and Geographical Distribution
Revenue from
international sources approximated $1,435 and $55 for the three months ended March 31, 2023 and 2022, respectively.
Our operations comprise
a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream
into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category,
for the three months ended March 31, 2023 and 2022 are as follows:
| |
Three months ended March 31, | |
Product Category | |
2023 | | |
2022 | |
Solésence | |
$ | 5,044 | | |
$ | 5,560 | |
Personal Care Ingredients | |
| 3,544 | | |
| 2,382 | |
Advanced Materials | |
| 869 | | |
| 214 | |
Total Sales | |
$ | 9,457 | | |
$ | 8,156 | |
(12) |
Commitments and Contingencies |
|
|
On
August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging
that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the
one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity
provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other
than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel
fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court
(the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision
of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement,
nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient.
Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey
Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not
consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint,
denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration
similar to that Nanophase sought in its Illinois Complaint. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s
Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in that litigation is ongoing. Management believes
at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement
and governing law. Per ASC 450 for the period ending March 31, 2023, an estimated contingent loss was not recorded, and an estimated
range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable.
(13) |
Accounting Standards Adopted During 2023 |
|
|
On
January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement
of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial
instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables,
the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities.
As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions,
and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument.
Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with
similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable
forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.
This
differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve,
management must now also consider current events as well as the future macroeconomic environment when making such loss assessments.
On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in
the amount of $203.